Core Product Advantages

1. High Efficiency and Accuracy

   Adopts high-precision next-generation sequencing technology to detect and analyze disease-related drug gene polymorphisms with high sensitivity and accuracy, and efficiently completes the whole detection and analysis process, ensuring the reliability of test results to support clinical precise medication decision-making.

2. Authoritative Guidance

   Based on authoritative pharmacogenomic research evidence and clinical chronic disease medication guidelines, the test results provide professional and authoritative reference for the rational use of antihypertensive, lipid-lowering, hypoglycemic and anti-hyperuricemia drugs, standardizing the clinical medication process.

3. Convenient Operation

   Features a streamlined and standardized detection process, with simple steps of informed consent, sample collection and experimental operation, easy to implement in clinical institutions, and suitable for large-scale clinical testing and personalized medication assessment of chronic disease patients.

Key Detection Content

Applicable Population

1. Patients taking antihypertensive, lipid-lowering, hypoglycemic or anti-hyperuricemia drugs for the first time
2. Patients with the four metabolic diseases taking multiple related drugs simultaneously or for a long time
3. Patients who have an unsatisfactory therapeutic response to a specific drug for the four diseases
4. Patients who have experienced drug adverse reactions themselves or with a family history of such reactions for the four diseases
5. Special high-risk medication groups (those with impaired liver or kidney function, the elderly, children, etc.) with the four diseases
6. Patients with the four metabolic diseases who attach importance to safe and rational medication

Clinical Significance

1. Individualized Precision Medicine

   From the genetic level, it clarifies the individual differences in drug metabolism and response of patients with the four chronic diseases, helps clinicians formulate personalized and targeted precise medication plans, and realizes the transformation from empirical medication to genetic-guided precision medication.

2. Reference for Clinical Rational Drug Use

   Provides professional pharmacogenomic reference for clinical medication decision-making of the four metabolic diseases, helps avoid irrational medication behaviors such as inappropriate drug selection and improper dosage, and improves the scientificity of chronic disease medication management.

3. Improve the Therapeutic Efficacy of Drugs

   Accurately predicts the drugs with good therapeutic effect for individual patients, helps clinicians select the most suitable first-line medication, and effectively improves the overall therapeutic effect of antihypertensive, lipid-lowering, hypoglycemic and anti-hyperuricemia treatments.

4. Reduce the Risk of Adverse Drug Reactions

   Identifies patients with high risk of adverse drug reactions in advance, guides clinicians to avoid high-risk drugs or timely adjust medication dosage, reduces the occurrence of drug-induced injuries, and significantly improves the safety of clinical medication for chronic metabolic diseases.

Standard Detection Process

1. Informed consent signing by the tested person
2. Clinical sample collection
3. Nucleic acid extraction and quality control
4. Pharmacogenomic gene library preparation
5. High-throughput next generation sequencing
6. Professional bioinformatics data analysis and gene polymorphism interpretation
7. Formal pharmacogenomic test report reporting

Rapid Lead Time